Farmas USA

http://seekingalpha.com/article/2315985-why-immunotherapies-have-made-delmars-lead-drug-a-necessity-in-brain-cancer

Edito: en Yahoo, el precio objetivo lo fijan en más de 5$....

enumera implicaciones de cambiar un titulo!!!

CYTX Joder, al final pone Resumen. He ido directamente ahí Ana, pero no me entero de na. No te pido que me lo resumas, eh¡¡ ya me buscaré la vida

Yo no tengo que valorar implicaciones, aunque para empezar implica orden y respeto. Es lo que me dijeron que se hacía aquí cuando yo llegué.

CYTX

Ahora me parece más mona. Tendré que leer el informe con calma. El "resumen" anterior era solo de una parte de un informe trimestral. La info iba por orden descendente de cronología.

Resumen trimestral nuevo

Upcoming Catalysts:

Complete enrollment of US ACT-OA trial and examine data
Initiate enrollment of US scleroderma STAR trial
Publication of SCLERADEC-I 12 month data and initiation of enrollment of French SCLERADEC-II trial
Begin enrollment of MHLW funded Japanese stress urinary incontinence trial
Complete core research and development activities for the next generation Celution System and file for IDE in the U.S. for a BARDA funded burn trial

Selected Q1 Highlights:

Cytori received FDA IDE full approval for Pivotal Phase III trial, STAR TRIAL, to evaluate ECCS-50 in treating hand dysfunction associated with scleroderma – Jan’ 2015
FDA approved an increase in number of STAR trial sites from 12 to 20 – Feb’ 2015
Enrollment began for ACT-OA, a 90 patient, US Phase II trial, to study ECCO-50 in treating osteoarthritis of the knee - Feb’ 2015
Cytori and Lorem Vascular were granted regulatory clearance for Cytori Celution® System by the State Food and Drug Administration of the People’s Republic of China – Apr’ 2015
Cytori received initial purchase order of Celution devices and 1,100 consumable sets from Lorem Vascular, our Chinese Licensee – Apr’ 2015
Cytori was granted orphan drug status for treatment of scleroderma in European Union – Apr’ 2015
Cytori reported top line 12 month follow-up data on SCLERADEC-I Trial – Apr’ 2015
Cytori presented preclinical and mechanistic data supporting use of Cytori Cell Therapy™ in wounds combining thermal burn and radiation exposure - Apr’ 2015

“Enrollment in the ACT-OA trial is proceeding as anticipated; we now have 38 patients enrolled into this 90 patient trial. We are confident that we will complete enrollment this year” said Dr. Steven Kesten, Chief Medical Officer of Cytori Therapeutics. “In addition, the Scleroderma program is a key component of our overall clinical strategy and we are very active in laying the groundwork to begin the U.S. trial in the next few months”.

aunque no hay ninguna implicacion, procuraré no alterar el orden, si tanto os desconcierta.
en lo que concierne al respeto, a mi me sobra , lo he tenido y siempre lo tendré.

Parece ser que hoy se anuncian los earnings de nuestros cromos...!!!

CYTX algo de esto iba a contestarte. Parece que además de quemaduras andan detrás de no se que historias en las manos. El último subidón, en febrero, fue porque le ampliaron el número de centros del estudio. Se desmarcó con un 56% ese día.